A patient was diagnosed with
neuroblastoma at the age of 2."
一个2岁的患者被诊断为神经母细胞瘤。
The treatment plan for
neuroblastoma often includes chemotherapy and surgery.
治疗神经母细胞瘤通常包括化疗和手术。
Neuroblastoma is a rare type of cancer that originates in nerve cells.
神经母细胞瘤是一种罕见的起源于神经细胞的癌症。
The survival rate for childhood
neuroblastoma has significantly improved over the years.
儿童神经母细胞瘤的存活率近年来有了显著提高。
A new drug has shown promise in treating advanced
neuroblastoma cases.
一种新药在治疗晚期神经母细胞瘤方面显示出前景。
Parents are often faced with difficult decisions about chemotherapy for their child's
neuroblastoma.
父母常常需要在孩子患神经母细胞瘤时艰难地决定是否进行化疗。
The tumor can spread to other parts of the body, including the abdomen and bones.
这种肿瘤可能扩散到身体的其他部位，如腹部和骨骼。
Neuroblastoma is most common in children under 1 year old.
神经母细胞瘤在1岁以下的儿童中最常见。
Research continues to uncover new genetic factors in
neuroblastoma development.
研究持续揭示神经母细胞瘤发展的新遗传因素。
Support groups provide emotional and informational assistance for families affected by
neuroblastoma.
支持团体为受到神经母细胞瘤影响的家庭提供情感和信息支持。
Nasdaq-listed Chinese biopharmaceutical company BeiGene hosted a public welfare salon on neuroblastoma on Sunday, aiming at raising public awareness of the disease and increasing drug accessibility to benefit more patients.
中国生物制药公司 BeiGene 在周日举办了一场关于神经母细胞瘤的公益沙龙，旨在提高公众对这种疾病的认识，并增加药物的可及性，以惠及更多的患者。
The salon invited children with neuroblastoma and their families, healthcare professionals, public welfare organizations and government authorities, to discuss the solution to cure the disease — a tumor that occurs in children.
该沙龙邀请了患有神经母细胞瘤的儿童及其家庭、医疗专业人员、公共福利组织和政府机构，共同讨论治愈这种疾病的方法——神经母细胞瘤是一种发生在儿童身上的肿瘤。
Neuroblastoma patients are normally under 15 years old, and half of the patients of their first attack are at the age of less than 2 years old.
神经母细胞瘤患者通常年龄在15岁以下，首次发病的一半患者年龄小于2岁。
Although it has low incidence, due to high degree of malignancy, rapid disease progression and difficult treatment, neuroblastoma is often referred to as the "king of childhood tumors".
神经母细胞瘤虽然发病率较低，但由于其高度恶性、疾病进展迅速和治疗困难，常被称为“儿童肿瘤之王”。
Zhao Qiang, vice-dean of the Cancer Institute & Hospital of Tianjin Medical University, said: "Generally speaking, if treated at an early stage, children with neuroblastoma have good chances to realize good prognosis.
天津医科大学肿瘤医院副院长赵强表示：“一般来说，如果在早期阶段得到治疗，神经母细胞瘤儿童实现良好预后的可能性较大。”
Wang Huanmin, a doctor at Beijing Children's Hospital of Capital Medical University, said "compared to developed countries, China's treatment level of neuroblastoma needs to be improved urgently.
北京儿童医院首都医科大学附属北京儿童医院的王欢民医生表示：“与发达国家相比，中国对神经母细胞瘤的治疗水平迫切需要提高。”
""Seeing my previous little patient with neuroblastoma standing here at the salon, blossoming into a healthy, beautiful young lady, is a real encouragement for me.
看到我之前治疗过的神经母细胞瘤小病人站在这里，成长为一个健康美丽的年轻女士，真的让我深受鼓舞。
Although neuroblastoma is an overwhelming rare tumor, it is curable.
虽然神经母细胞瘤是一种极其罕见的肿瘤，但它是可以治愈的。
At the beginning of last year, BeiGene worked with United Kingdom-based biopharmaceutical company EUSA Pharma to introduce a monoclonal antibody drug for neuroblastoma for Chinese patients.
去年年初， BeiGene与英国生物制药公司EUSA Pharma合作，为中国患者引进了一种针对神经母细胞瘤的单克隆抗体药物。
With the introduction of the monoclonal antibody drug, neuroblastoma patients are able to get medical treatment, bringing a chance of survival and cure for them.
随着单克隆抗体药物的引入，神经母细胞瘤患者现在能够接受医疗治疗，从而为他们带来了生存和治愈的希望。
未经许可，严禁转发。QQ交流群：688169419